Skip to main content
SpringerLink
Log in

No Influence of Food on the Pharmacokinetics, Pharmacodynamics or Tolerability of the 24mg and 36mg Oral Tablet Formulations of Ximelagatran

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: To assess the potential effects of food on the pharmacokinetics and tolerability/safety of ximelagatran, an oral direct thrombin inhibitor developed for the prevention and treatment of thromboembolic disease that is rapidly bioconverted to its active form, melagatran.

Design and study participants: In two open-label, randomised, crossover studies, healthy male and female volunteers received oral ximelagatran as a single 24mg tablet (study 1, n = 30) or a single 36mg tablet (study 2, n = 50). Potential effects of food on the pharmacodynamics (activated partial thromboplastin time; APTT) of the 36mg tablet were also investigated in study 2.

Results: For the 24mg tablet, the 90% confidence intervals (CIs) and least-squares mean estimates for the ratio of the tablet with food to the tablet without food fell within the predefined bounds demonstrating no effect on area under the melagatran concentration-time curve (AUC ratio = 0.94 [90% CI 0.90, 0.99]) or maximum plasma concentration (Cmax ratio = 0.88 [90% CI 0.82, 0.95]). The same result was observed for the 36mg tablet (AUC ratio = 1.07 [90% CI 1.03, 1.12]; Cmax ratio = 1.05 [90% CI 0.98, 1.12]). Melagatran AUC normalised for differences in bodyweight was comparable between women and men administered the 24mg or 36mg tablet without food. In addition, food did not clinically significantly alter the melagatran-induced prolongation of the APTT of the 36mg tablet. Ximelagatran was well tolerated with or without food.

Conclusion: The pharmacokinetics (AUC, Cmax), pharmacodynamics (APTT) and tolerability of melagatran after administration of oral ximelagatran tablets were not affected by food.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Fig. 2
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Hrebickova L, Nawarskas JJ, Anderson JR. Ximelagatran: a new oral anticoagulant. Heart Dis 2003; 5: 397–408

    Article  PubMed  CAS  Google Scholar 

  2. Da Silva MS, Sobel M. Anticoagulants: to bleed or not to bleed, that is the question. Semin Vasc Surg 2002; 15: 256–67

    Article  Google Scholar 

  3. Pinede L, Duhaut P, Ninet J. Management of oral anticoagulants in the treatment of venous thromboembolism. Eur J Intern Med 2001; 12: 75–85

    Article  PubMed  CAS  Google Scholar 

  4. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41–7

    Article  PubMed  CAS  Google Scholar 

  5. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441–7

    Article  PubMed  CAS  Google Scholar 

  6. Eriksson BI, Agnelli G, Cohen AT, et al. on behalf of the EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490–6

    Article  PubMed  CAS  Google Scholar 

  7. Francis CW, Berkowitz SD, Comp PC, et al. for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703–12

    Article  PubMed  CAS  Google Scholar 

  8. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691–8

    Article  Google Scholar 

  9. Schulman S, Wåhlander K, Lundström T, et al. for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713–21

    Article  PubMed  CAS  Google Scholar 

  10. Wallentin L, Wilcox R, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the randomized controlled ESTEEM trial. Lancet 2003; 362: 789–97

    Article  PubMed  CAS  Google Scholar 

  11. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003; 109: S9–15

    Article  PubMed  CAS  Google Scholar 

  12. Sarich TC, Johansson S, Schützer K-M, et al. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 2004; 44: 388–93

    Article  PubMed  CAS  Google Scholar 

  13. Sarich TC, Schützer KM, Dorani H, et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004; 44: 928–34

    Article  PubMed  CAS  Google Scholar 

  14. Teng R, Sarich TC, Eriksson JG, et al. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 2004; 44: 1063–71

    Article  PubMed  CAS  Google Scholar 

  15. Sarich TC, Schützer KM, Wollbratt M, et al. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 2004; 44: 935–41

    Article  PubMed  CAS  Google Scholar 

  16. Dorani H, Schützer K-M, Wollbratt M, et al. No clinically significant interaction between the oral direct thrombin inhibitor ximelagatran and amiodarone, atorvastatin or digoxin [abstract no. P1-98]. Clin Pharmacol Ther 2004; 75(2): 78

    Google Scholar 

  17. Dorani H, Schützer K, Sarich TC, et al. Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran [abstract]. Clin Pharmacol Ther 2004; 75: P78

    Google Scholar 

  18. Dorani H, Schützer K, Sarich TC, et al. No effect of amoxicillin, doxycycline, and ciprofloxacin on the pharmacokinetics and pharmacodynamics of ximelagatran [abstract no. PI-147]. Clin Pharmacol Ther 2005; 77(2): 46

    Article  Google Scholar 

  19. Dorani H, Schützer K, Sarich TC, et al. The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with azithromycin and cefuroxime [abstract no. PII-126]. Clin Pharmacol Ther 2005; 77(2): 83

    Article  Google Scholar 

  20. Johansson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381–92

    Article  PubMed  CAS  Google Scholar 

  21. Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59: 35–43

    PubMed  CAS  Google Scholar 

  22. Larsson M, Logren U, Ahnoff M, et al. Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2002; 766: 47–55

    Article  CAS  Google Scholar 

  23. Wernevik LC, Nyström P, Johnsson G, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clin Pharmacokinet. In press

  24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    Article  PubMed  CAS  Google Scholar 

  25. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171–81

    Article  PubMed  CAS  Google Scholar 

  26. Grind M, Hamren B, Baathe S, et al. Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling [abstract no. MPI-99]. Clin Pharmacol Ther 2002; 71: P31

    Google Scholar 

  27. Sarich TC, Teng R, Peters GR, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran. Clin Pharmacokinet 2003; 42: 485–92

    Article  PubMed  CAS  Google Scholar 

  28. Johansson LC, Andersson M, Fager G, et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003; 42: 475–84

    Article  PubMed  CAS  Google Scholar 

  29. Warfarin Prescribing Information. Pomona (NY): Barr Laboratories Inc., 2002 Nov

  30. Hirsh J. Current anticoagulant therapy: unmet clinical needs. Thromb Res 2003; 109Suppl. 1: S1–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by AstraZeneca. The authors acknowledge the assistance of Jane Saiers, PhD, in writing the manuscript.

Author information

Authors and Affiliations

  1. AstraZeneca R&D, S-431 83, Mölndal, Sweden

    Eva Ersdal, Kajs-Marie Schützer, Carina Lönnerstedt, Lis Ohlsson, Ulrika Wall & Ulf G Eriksson

Authors
  1. Eva Ersdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kajs-Marie Schützer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carina Lönnerstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lis Ohlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulrika Wall
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulf G Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Ersdal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ersdal, E., Schützer, KM., Lönnerstedt, C. et al. No Influence of Food on the Pharmacokinetics, Pharmacodynamics or Tolerability of the 24mg and 36mg Oral Tablet Formulations of Ximelagatran. Clin. Drug Investig. 25, 425–433 (2005). https://doi.org/10.2165/00044011-200525070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525070-00001

Keywords

Search

Navigation